1Obata J,Nakamura T,Kuroyanaga R,et al.Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats[].Kidney International.1997
2Hunsicker LG,Atkins RC,Lewis JB,et al.Impact of irbesartan,blood pressure control,and proteinuria on renal outcomes in the lrbesartan Diabetic NephropathyTrial[].KidneyInt Supp.2004
3Nskao N,Yoshimura A,Morita H,et al.Combination therapy of an-giotensin-Ⅱreceptor blocker and angiotensin-converting-enzyme in-hibitor in non-diabetic renal disease(COOPERATE):a randomised con-trolled trial[].The Lancet.2003
4Leenen FH,Yuan B.Prevention of hypertension by irbesartan in dahl S rats relates to central angiotensin II type I receptor blockade[].Journal of Hypertension.2001
5Shahinfar S,Simpson RL,Carides AD et al.Safety of losartan in hypertensive patients with thiazide - induced hyperuricemia[].Kidney International.1999
6Brenner BM,Cooper ME,Zeeuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[].New England Journal of Medicine The.2001
7Parving HH,Lehnert H,Brochner-Mortensen J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[].The New England Journal of Medicine.2001
8Giancarlo V,Nigel M,Wheeldon.Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus[].Circulation.2002
9Rosso D,Minutolo R,Pisani A,et al.Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy[].American Journal of Kidney Diseases.2001
